NextCure Inc (nasdaq:NXTC) Share Price

Company Profile

Business description
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USA
T: +1 240 399-4900
https://www.nextcure.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
40

Recommended

These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.

Morningstar | 11 November 2026

There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.

Malik Ahmed Khan, CFA | 11 November 2026

Strong fundamentals meet a demanding valuation.

Esther Holloway | 11 November 2026

Index	Last price	Change	% Change
All Ordinaries	9,291.30	23.50	0.25%
CAC 40	8,332.87	54.28	0.66%
DAX 40	26,662.77	315.32	1.20%
Dow JONES (US)	52,486.49	254.60	0.49%
FTSE 100	10,835.47	83.88	0.78%
HKSE	24,396.20	160.84	-0.65%
NASDAQ	25,466.19	400.32	1.60%
Nikkei 225	61,321.43	861.85	1.43%
NZX 50 Index	14,234.27	66.86	0.47%
S&P 500	7,619.38	98.45	1.31%
S&P/ASX 200	9,153.20	24.20	0.27%
SSE Composite Index	3,683.62	19.89	0.54%